News Pronto
 

ACN Newswire

Read more press releases from ACN Newswire here

Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma

  • Written by ACN Newswire

image

Paris, France and Cambridge, Massachusetts, USA, Oct 23, 2017 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has completed patient inclusion for the Phase II/III trial (Act.In.Sarc) of its lead product...

Read more: Nanobiotix Completes Patient Inclusion for Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma